Abstract
Bone tumor is a kind of rare cancer, the location of which is mainly in bone tissue as well as cartilage tissue. Bone tumor is mainly classified into benign and malignant types. The survival rate of patients with bone tumors can be considerably improved by early detection, and the danger of amputation caused by bone tumors can be greatly reduced. In this study, we first screened the top 25% serum miRNAs with the greatest variance in patients with malignant and benign bone tumor and healthy individuals. The expression of serum miRNAs in patients with bone tumor was then examined using unsupervised clustering and PCA, and the results revealed that the overall expression of serum miRNAs was ineffective in distinguishing patients with benign/malignant bone tumors. Subsequently, we screened 19 miRNA biomarkers that could be used to determine the benign/malignant bone tumor of patients by LASSO logistic regression. These genes were validated using ROC curves. Results showed that there were 11 miRNAs that could accurately distinguish benign/malignant bone tumor alone. These 11 miRNAs were, namely, hsa-miR-192-5p, hsa-miR-137, hsa-miR-142-3p, hsa-miR-155-3p, hsa-miR-1205, hsa-miR-1273a, hsa-miR-3187-3p, hsa-miR-1255b-2-3p, hsa-miR-1288-5p, hsa-miR-6836-5p, and hsa-miR-6862-5p. Next, we established a diagnostic model using logistic regression and validated the diagnostic model using ROC curves; the result of which showed that the model had good diagnostic efficacy. Then, we also verified that the diagnostic model established by these 11 miRNAs could distinguish patients with benign/malignant bone tumor using unsupervised clustering as well as PCA. Finally, by using qPCR, we validated the expression of 11 miRNAs in the serum of patients with malignant and benign bone tumors, as well as healthy volunteers. The results were consistent with the trend of miRNAs expression in public databases. In summary, we examined the differential expression of serum miRNAs in individuals with benign and malignant bone tumors and discovered 11 miRNA biomarkers that could be utilized to discriminate between the two.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
The data and materials in the current study are available from the corresponding author on reasonable request.
References
Asano N, Matsuzaki J, Ichikawa M, Kawauchi J, Takizawa S, Aoki Y, Sakamoto H, Yoshida A, Kobayashi E, Tanzawa Y et al (2019) A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes. Nat Commun 10:1299. https://doi.org/10.1038/s41467-019-09143-8
Croset M, Kan C, Clezardin P (2015) Tumour-derived miRNAs and bone metastasis. Bonekey Rep 4:688. https://doi.org/10.1038/bonekey.2015.56
Erdogan O, Gurkan V (2020) Benign bone tumors of hand and wrist: evaluation of diagnosis and treatment. Jt Dis Relat Surg 31:81–87. https://doi.org/10.5606/ehc.2020.72162
Fabisiewicz A, Grzybowska E (2017) CTC clusters in cancer progression and metastasis. Med Oncol 34:12. https://doi.org/10.1007/s12032-016-0875-0
Ferguson JL, Turner SP (2018) Bone cancer: diagnosis and treatment principles. Am Fam Physician 98:205–213
Fletcher C, Hogendoorn P, Mertens F (2013) WHO classification of tumors of soft tissue and bone
Hameed M, Dorfman H (2011) Primary malignant bone tumors—recent developments. Semin Diagn Pathol 28:86–101. https://doi.org/10.1053/j.semdp.2011.02.002
Hyun S, Lee JH, Jin H, Nam J, Namkoong B, Lee G, Chung J, Kim VN (2009) Conserved MicroRNA miR-8/miR-200 and its target USH/FOG2 control growth by regulating PI3K. Cell 139:1096–1108. https://doi.org/10.1016/j.cell.2009.11.020
Kerr DL, Dial BL, Lazarides AL, Catanzano AA, Lane WO, Blazer DG 3rd, Brigman BE, Mendoza-Lattes S, Eward WC, Erickson ME (2019) Epidemiologic and survival trends in adult primary bone tumors of the spine. Spine J 19:1941–1949. https://doi.org/10.1016/j.spinee.2019.07.003
Kim AA, Rachid Zaim S, Subbian V (2020) Assessing reproducibility and veracity across machine learning techniques in biomedicine: a case study using TCGA data. Int J Med Inform 141:104148. https://doi.org/10.1016/j.ijmedinf.2020.104148
Lee YS, Dutta A (2009) MicroRNAs in cancer. Annu Rev Pathol 4:199–227. https://doi.org/10.1146/annurev.pathol.4.110807.092222
Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z et al (2011) miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 9:824–833. https://doi.org/10.1158/1541-7786.MCR-10-0529
Lupu A, Ene R, Cursaru A, Anghelescu D, Popescu E, Cîrstoiu C (2018) Indication of amputation after tumoral arthroplasty. Rom J Orthop Surg Traumatol 1:9–9. https://doi.org/10.2478/rojost-2018-0020
Mengual L, Lozano JJ, Ingelmo-Torres M, Izquierdo L, Musquera M, Ribal MJ, Alcaraz A (2016) Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers. BMC Cancer 16:76. https://doi.org/10.1186/s12885-016-2127-2
Murahashi Y, Iba K, Teramoto A, Emori M, Okada Y, Kamiya T, Watanabe K, Yamashita T (2020) Clinical features of bone and soft tissue tumors of the foot and ankle: Results from a retrospective single-center case-series. J Orthop Sci. https://doi.org/10.1016/j.jos.2020.08.016
Nugent M (2015) microRNA and bone cancer. Adv Exp Med Biol 889:201–230. https://doi.org/10.1007/978-3-319-23730-5_11
Pan Y, Sun Y, Liu Z, Zhang C (2020) miR1925p upregulation mediates the suppression of curcumin in human NSCLC cell proliferation, migration and invasion by targeting cMyc and inactivating the Wnt/betacatenin signaling pathway. Mol Med Rep 22:1594–1604. https://doi.org/10.3892/mmr.2020.11213
Pardini B, Sabo AA, Birolo G, Calin GA (2019) Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers. https://doi.org/10.3390/cancers11081170
Peng P, Chen T, Wang Q, Zhang Y, Zheng F, Huang S, Tang Y, Yang C, Ding W, Ren D et al (2019) Decreased miR-218-5p levels as a serum biomarker in bone metastasis of prostate cancer. Oncol Res Treat 42:165–185. https://doi.org/10.1159/000495473
Penyige A, Marton E, Soltesz B, Szilagyi-Bonizs M, Poka R, Lukacs J, Szeles L, Nagy B (2019) Circulating miRNA profiling in plasma samples of ovarian cancer patients. Int J Mol Sci. https://doi.org/10.3390/ijms20184533
Qadir MI, Faheem A (2017) miRNA: a diagnostic and therapeutic tool for pancreatic cancer. Crit Rev Eukaryot Gene Expr 27:197–204. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2017019494
Rasulova N, Lyubshin V, Arybzhanov D, Krylov V, Khodjibekov M (2013) Effectiveness of bone metastases treatment by sm-153 oxabifore in combination with monoclonal antibody denosumab (xgeva): first experience. World J Nucl Med 12:19–23. https://doi.org/10.4103/1450-1147.113942
Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB (2012) miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther 11:1166–1173. https://doi.org/10.1158/1535-7163.MCT-12-0100
Sun J, Cai X, Yung MM, Zhou W, Li J, Zhang Y, Li Z, Liu SS, Cheung ANY, Ngan HYS et al (2019) miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene 38:564–580. https://doi.org/10.1038/s41388-018-0459-x
Toyoda Y, Shinohara N, Harabayashi T, Abe T, Akino T, Sazawa A, Nonomura K (2007) Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol 52:163–168. https://doi.org/10.1016/j.eururo.2006.10.060
Vijayan S, Jain C, Naik MA, Rao SK (2019) Osteoid osteoma of the calcaneus misdiagnosed as subtalar sprain. Indian J Cancer 56:350–353. https://doi.org/10.4103/ijc.IJC_146_18
Weber K, Damron TA, Frassica FJ, Sim FH (2008) Malignant bone tumors. Instr Course Lect 57:673–688
Ying SY, Chang DC, Lin SL (2008) The microRNA (miRNA): overview of the RNA genes that modulate gene function. Mol Biotechnol 38:257–268. https://doi.org/10.1007/s12033-007-9013-8
Zhang C, Yao C, Li H, Wang G, He X (2014) Combined elevation of microRNA-196a and microRNA-196b in sera predicts unfavorable prognosis in patients with osteosarcomas. Int J Mol Sci 15:6544–6555. https://doi.org/10.3390/ijms15046544
Zhou J, Chang L, Guan Y, Yang L, Xia X, Cui L, Yi X, Lin G (2016) Application of circulating tumor DNA as a non-invasive tool for monitoring the progression of colorectal cancer. PLoS ONE 11:e0159708. https://doi.org/10.1371/journal.pone.0159708
Zhou X, Lu Z, Wang T, Huang Z, Zhu W, Miao Y (2018) Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: a miRNA expression analysis. Gene 673:181–193. https://doi.org/10.1016/j.gene.2018.06.037
Zhou Z, Fan T, Yan Y, Zhang S, Zhou Y, Deng H, Cai X, Xiao J, Song D, Zhang Q et al (2019) One stone with two birds: Phytic acid-capped platinum nanoparticles for targeted combination therapy of bone tumors. Biomaterials 194:130–138. https://doi.org/10.1016/j.biomaterials.2018.12.024
Acknowledgements
Not applicable.
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
YM and JW conceived and designed the study. YM, JW, and TL performed the experiments. XT provided the mutants. SZ wrote the paper. YM, JW, and TL reviewed and edited the manuscript. All authors read and approved the manuscript.
Corresponding author
Ethics declarations
Competing interest
The authors declare that they have no conflict of interest.
Ethics Approval and Consent to Participate
Not applicable.
Consent for Publication
All authors consent to submit the manuscript for publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhang, Y., Hu, J., Li, T. et al. Construction of a Diagnostic Model for Distinguishing Benign or Malignant Bone Cancer by Mining miRNA Expression Data. Biochem Genet 61, 299–315 (2023). https://doi.org/10.1007/s10528-022-10259-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10528-022-10259-8